{"id":"bunazosin","rwe":[{"pmid":"37955611","year":"2023","title":"Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion.","finding":"","journal":"Investigative ophthalmology & visual science","studyType":"Clinical Study"},{"pmid":"24684300","year":"2014","title":"Repetitive hypoglycemia increases circulating adrenaline level with resultant worsening of intimal thickening after vascular injury in male Goto-Kakizaki rat carotid artery.","finding":"","journal":"Endocrinology","studyType":"Clinical Study"},{"pmid":"24436989","year":"2013","title":"Involvement of nitric oxide production in the impairment of skin blood flow response to local cooling in diabetic db/db mice.","finding":"","journal":"European journal of pharmacology","studyType":"Clinical Study"},{"pmid":"27122680","year":"2013","title":"Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.","finding":"","journal":"Acta Cardiologica Sinica","studyType":"Clinical Study"},{"pmid":"20966593","year":"2010","title":"Restraint stress induces connexin-43 translocation via α-adrenoceptors in rat heart.","finding":"","journal":"Circulation journal : official journal of the Japanese Circulation Society","studyType":"Clinical Study"}],"tags":[{"label":"bunazosin","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-1A adrenergic receptor","category":"target"},{"label":"ADRA1A","category":"gene"},{"label":"ADRA1B","category":"gene"},{"label":"ADRA2B","category":"gene"},{"label":"Active","category":"status"},{"label":"Essential hypertension","category":"indication"},{"label":"Adrenergic Agents","category":"pharmacology"},{"label":"Adrenergic Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-1 Receptor Antagonists","category":"pharmacology"},{"label":"Adrenergic alpha-Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"detantol","offLabel":[],"synonyms":["bunazosin hydrochloride","detantol","bunazosin","bunazosin HCl"],"timeline":[],"brandName":"Detantol","ecosystem":[{"indication":"Essential hypertension","otherDrugs":[{"name":"alacepril","slug":"alacepril","company":"Par Pharm"}],"globalPrevalence":1280000000}],"mechanism":{"target":"Alpha-1A adrenergic receptor","targets":[{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"ADRA1B","source":"DrugCentral","target":"Alpha-1B adrenergic receptor","protein":"Alpha-1B adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"NQO2","source":"DrugCentral","target":"Ribosyldihydronicotinamide dehydrogenase [quinone]","protein":"Ribosyldihydronicotinamide dehydrogenase [quinone]"}],"modality":"Small Molecule","drugClass":"bunazosin","explanation":"Think of it like a traffic light: when the alpha-1A receptor is active, it's like a red light that makes blood vessels constrict. By blocking this receptor, Detanidol is like flipping the light to green, allowing blood vessels to relax and blood pressure to decrease.","oneSentence":"Detanidol works by blocking the alpha-1A adrenergic receptor, which helps to relax blood vessels and lower blood pressure.","technicalDetail":"Detanidol acts as a selective alpha-1A adrenergic receptor antagonist, competing with endogenous norepinephrine for binding sites on the receptor, thereby inhibiting vasoconstriction and reducing peripheral resistance."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/429","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BUNAZOSIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BUNAZOSIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:04:09.465398","biosimilars":[],"competitors":[{"drugName":"alfuzosin","drugSlug":"alfuzosin","fdaApproval":"2003-06-12","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amfetamine","drugSlug":"amfetamine","fdaApproval":"1955-09-09","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amlodipine","drugSlug":"amlodipine","fdaApproval":"1992-07-31","patentExpiry":"Feb 24, 2041","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"apomorphine","drugSlug":"apomorphine","fdaApproval":"2004-04-20","patentExpiry":"Jun 11, 2030","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"asenapine","drugSlug":"asenapine","fdaApproval":"2009-08-13","patentExpiry":"Sep 22, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"azelastine","drugSlug":"azelastine","fdaApproval":"1996-11-01","patentExpiry":"Jun 4, 2028","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"benzphetamine","drugSlug":"benzphetamine","fdaApproval":"1960-10-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"brexpiprazole","drugSlug":"brexpiprazole","fdaApproval":"2015-07-10","patentExpiry":"Oct 12, 2032","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"bunazosin","indications":{"approved":[{"name":"Essential hypertension","source":"DrugCentral","snomedId":59621000,"regulator":"FDA","usPrevalence":119900000,"globalPrevalence":1280000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"alfuzosin","brandName":"alfuzosin","genericName":"alfuzosin","approvalYear":"2003","relationship":"same-target"},{"drugId":"amfetamine","brandName":"amfetamine","genericName":"amfetamine","approvalYear":"1955","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amlodipine","brandName":"amlodipine","genericName":"amlodipine","approvalYear":"1992","relationship":"same-target"},{"drugId":"apomorphine","brandName":"apomorphine","genericName":"apomorphine","approvalYear":"2004","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"asenapine","brandName":"asenapine","genericName":"asenapine","approvalYear":"2009","relationship":"same-target"},{"drugId":"azelastine","brandName":"azelastine","genericName":"azelastine","approvalYear":"1996","relationship":"same-target"},{"drugId":"benzphetamine","brandName":"benzphetamine","genericName":"benzphetamine","approvalYear":"1960","relationship":"same-target"},{"drugId":"brexpiprazole","brandName":"brexpiprazole","genericName":"brexpiprazole","approvalYear":"2015","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT07497412","phase":"","title":"The Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea","status":"ACTIVE_NOT_RECRUITING","sponsor":"King's College London","startDate":"2026-01-01","conditions":["Obstructive Sleep Apnea"],"enrollment":10000,"completionDate":"2027-06"},{"nctId":"NCT07287254","phase":"NA","title":"The Effect of Different Types of Music on Pain and Anxiety During Wound Care Procedures in Patients With Venous Ulcers","status":"COMPLETED","sponsor":"Izmir Katip Celebi University","startDate":"2023-05-02","conditions":["Venous Leg Ulcer","Pain","Anxiety"],"enrollment":97,"completionDate":"2024-09-20"},{"nctId":"NCT07065227","phase":"NA","title":"Potential Benefits of Sonic Augmentation Technology in Music","status":"SUSPENDED","sponsor":"University of Florida","startDate":"2025-09-24","conditions":["Biobehavioral State","Sonic Augmentation Technology","Oxytocin","Autonomic Reactivity"],"enrollment":36,"completionDate":"2026-05-10"},{"nctId":"NCT06856785","phase":"NA","title":"Management of Non-Organic Dysphonia in Adults.","status":"RECRUITING","sponsor":"Sohag University","startDate":"2025-03","conditions":["Functional Dysphonia","Resonance Tube Voice Therapy","Smith Accent Method Therapy"],"enrollment":60,"completionDate":"2025-09"},{"nctId":"NCT01345318","phase":"PHASE2","title":"B0151005 Open-Label Extension Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-06","conditions":["Crohn's Disease"],"enrollment":191,"completionDate":"2016-03"},{"nctId":"NCT01287897","phase":"PHASE2","title":"A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-02","conditions":["Crohn's Disease"],"enrollment":250,"completionDate":"2015-02"},{"nctId":"NCT00130156","phase":"PHASE4","title":"Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-10","conditions":["High Blood Pressure"],"enrollment":93,"completionDate":"2009-03"},{"nctId":"NCT00268658","phase":"NA","title":"Clinical Use of Andante SmartStep System in Gait Rehabilitation","status":"UNKNOWN","sponsor":"Soroka University Medical Center","startDate":"","conditions":["Ankle Injuries","Femoral Neck Fractures"],"enrollment":60,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"007091","UNII":"9UUW4V7G2H","CHEBI":"CHEBI:31320","INN_ID":"5466","RXNORM":"19850","UMLSCUI":"C0054222","ChEMBL_ID":"CHEMBL188185","KEGG_DRUG":"D01887","DRUGBANK_ID":"DB12230","PUBCHEM_CID":"2472","SECONDARY_CAS_RN":"52712-76-2","MESH_SUPPLEMENTAL_RECORD_UI":"C018176"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"2.0 hours","clearance":"4.8 mL/min/kg","bioavailability":"44%","fractionUnbound":"0.06%","volumeOfDistribution":"0.72 L/kg"},"publicationCount":273,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"recentPublications":[{"date":"2023 Nov 1","pmid":"37955611","title":"Topical Application of Bunazosin Hydrochloride Suppresses Myopia Progression With an Increase in Choroidal Blood Perfusion.","journal":"Investigative ophthalmology & visual science"},{"date":"2014 Jun","pmid":"24684300","title":"Repetitive hypoglycemia increases circulating adrenaline level with resultant worsening of intimal thickening after vascular injury in male Goto-Kakizaki rat carotid artery.","journal":"Endocrinology"},{"date":"2013 Nov 15","pmid":"24436989","title":"Involvement of nitric oxide production in the impairment of skin blood flow response to local cooling in diabetic db/db mice.","journal":"European journal of pharmacology"},{"date":"2013 Jan","pmid":"27122680","title":"Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.","journal":"Acta Cardiologica Sinica"},{"date":"2010 Nov","pmid":"20966593","title":"Restraint stress induces connexin-43 translocation via α-adrenoceptors in rat heart.","journal":"Circulation journal : official journal of the Japanese Circulation Society"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Detanidol (Bunazosin) is a small molecule drug that targets the alpha-1A adrenergic receptor. It is classified as a bunazosin and is used to treat essential hypertension. The commercial status of Detanidol is unknown, and it is not FDA-approved. Key safety considerations include its short half-life of 2.0 hours and moderate bioavailability of 44%. Further research is needed to determine its off-patent status and generic manufacturers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}